<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02042950</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0259</org_study_id>
    <secondary_id>NCI-2014-01271</secondary_id>
    <nct_id>NCT02042950</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma</brief_title>
  <official_title>A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Onyx Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if carfilzomib can help control relapsed
      or refractory MCL. The safety of this drug will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drug Administration:

      If participant is found to be eligible for this study, they will begin the first cycle of
      treatment with carfilzomib. Each cycle is 28 days.

      On Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12:

        -  Participant will receive carfilzomib by vein over 30 minutes. The first 2 doses
           participant receives may be lower than later doses. This is to reduce the risk of an
           allergic reaction.

      On Days 1, 2, 15, and 16 of Cycles 13 and beyond:

        -  Participant will receive carfilzomib by vein over 30 minutes.

      Participant should drink at least 6-8 cups (8 ounces each) of fluid per day starting 2 days
      before their first day of treatment and for as long as their doctor asks them to. During
      Cycles 1 and 2, participant will receive fluids by vein before and after their dose of
      carfilzomib.

      Before participant receives carfilzomib, they will be given standard drugs (such as
      allopurinol, dexamethasone, antibiotics, anti-fungals, and/or anti-virals) to help decrease
      the risk of side effects. Participant may ask the study staff for information about how the
      drugs are given and their risks.

      When participant receives the drugs during Cycle 1 and on Day 1 of Cycle 2, they will be
      monitored for side effects for 1 hour after they receive the study drug.

      Study Visits:

      On Day 1 of all cycles:

        -  Participant will have a physical exam.

        -  Participant will have a neurological exam to check for weakness, numbness and pain in
           their hands and feet.

        -  Blood (about 2 tablespoons) will be drawn for routine tests.

        -  If participant's doctor thinks it is needed, they will have a bone marrow biopsy and/or
           aspiration to check the status of the disease.

        -  If participant's doctor thinks it is needed, they will have an ECHO or a MUGA.

        -  If participant is able to become pregnant, they will have a blood (about 1½ tablespoons)
           or urine pregnancy test. (Cycles 2 and beyond only)

      On Days 2, 9, and 16 of all cycles:

        -  Participant's vital signs will be measured.

      On Days 8 and 15 of all cycles:

        -  Participant will have a physical exam.

        -  Blood (about 2 tablespoons) will be drawn for routine tests.

        -  If participant is able to become pregnant, they will have a blood (about 1½ tablespoons)
           or urine pregnancy test.

      On Day 1 of Cycles 2, 4, 6, and so on up to Cycle 12, then every 3 cycles after that:

        -  If the study doctor thinks it is needed, participant will have a CT scan, MRI, PET scan,
           and/or PET/CT scan to check the status of the disease.

        -  If the study doctor thinks it is needed, participant will have a gastrointestinal
           endoscopy or colonoscopy.

      Length of Study:

      Participant may continue taking the study drug for up to 3 years. Participant will no longer
      be able to take the drug if the disease gets worse, if intolerable side effects occur, or if
      they are unable to follow study directions.

      Patient's participation on the study will be over once they have completed the long term
      follow-up phone calls.

      End-of-Treatment Visit:

      Within about 30 days, after participant finishes taking the study drug they will return to
      the clinic for the following tests and procedures:

        -  Participant will have a physical exam.

        -  Participant will have a neurological exam to check for weakness, numbness and pain in
           their hands and feet.

        -  Participant will have an EKG to check their heart function.

        -  Blood (about 3-5 tablespoons) will be drawn for routine tests and to check the status of
           the disease.

        -  Participant will have a CT scan and/or x-ray to check the status of the disease.

        -  Participant will have a PET/CT scan to check the status of the disease.

        -  If participant's doctor thinks it is needed, they will have a bone marrow biopsy and
           aspiration

        -  If participant's doctor thinks it is needed, they will have a
           colonoscopy/gastrointestinal endoscopy.

        -  If participant is able to become pregnant, they will have a blood (about 1½ tablespoons)
           or urine pregnancy test.

      Long Term Follow-Up:

      After participant's end-of-treatment visit, they will be called every 6 months for 1 year to
      see how they are doing and to find out about any other treatments they have received since
      they stopped study treatment. These calls will take about 2-3 minutes. In addition to the
      phone calls, participant's medical records may be reviewed as well.

      This is an investigational study. Carfilzomib is FDA approved and commercially available for
      the treatment of certain types of multiple myeloma. This drug is investigational for the
      treatment of MCL.

      Up to 60 participants will be enrolled on this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to poor accrual
  </why_stopped>
  <start_date type="Actual">July 14, 2014</start_date>
  <completion_date type="Actual">December 20, 2017</completion_date>
  <primary_completion_date type="Actual">December 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate of Carfilzomib</measure>
    <time_frame>21 months</time_frame>
    <description>To evaluate the efficacy of single agent carfilzomib in patients with relapsed/refractory MCL as measured by response rate.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Toxicity of Carfilzomib</measure>
    <time_frame>21 months</time_frame>
    <description>To further evaluate the toxicity of Carfilzomib in patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Post Treatment</measure>
    <time_frame>21 months</time_frame>
    <description>To estimate the response duration, progression free survival, time to failure and overall survival.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Carfilzomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carfilzomib given at a dose of 20*/56 mg/m^2 (* CFZ 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Starting dose: 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).</description>
    <arm_group_label>Carfilzomib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of mantle cell lymphoma.

          2. Patients must have relapsed or refractory MCL.

          3. Understand and voluntarily sign an IRB-approved informed consent form.

          4. Age &gt;/= 18 years at the time of signing the informed consent.

          5. Patients must have bi-dimensional measurable disease (bone marrow only involvement is
             acceptable).

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less

          7. Serum bilirubin &lt;1.5 mg/dl and Creatinine Clearance &gt;/= 30 mL/min, platelet count
             &gt;50,000/mm^3 and absolute neutrophil count (ANC) &gt; 1,000/mm^3. [Patients who have bone
             marrow infiltration by MCL are eligible if their ANC is ≥ 500/mm^3 (growth factor
             allowed) or their platelet level is equal to or &gt; than 30,000/mm^3.]. AST (SGOT) and
             ALT (SGPT) &lt; 2 x upper limit of normal or &lt; 5 x upper limit of normal if hepatic
             metastases are present. Uric acid within normal limits.

          8. Females of childbearing potential (FCBP)* must have a negative serum or urine
             pregnancy test within 30 days of initiation of therapy. * A female of childbearing
             potential is a sexually mature woman who: 1) has not undergone a hysterectomy or
             bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24
             consecutive months (i.e., has had menses at any time in the preceding 24 consecutive
             months).

          9. FCBP must agree to use a highly-effective form of birth control while taking the study
             drug and for 1 month after the last dose of study drug. Highly-effective forms of
             birth control include implants, injectables, birth control pills with 2 hormones, some
             intrauterine devices (IUDs), or having a sterilized partner. The type of birth control
             used must be discussed with and approved by the attending physician prior to
             initiation of study drug.

         10. Males must agree to use a condom with spermicide every time they have sex during the
             study and for 3 months after the last dose of study drug. They also must agree to not
             donate sperm during the study and for 3 months after the last dose of study drug.

         11. Patients must be willing to receive transfusions of blood products.

        Exclusion Criteria:

          1. Any serious medical condition including but not limited to, uncontrolled hypertension,
             uncontrolled diabetes mellitus, active/symptomatic coronary artery disease, chronic
             obstructive pulmonary disease (COPD), renal failure, active hemorrhage, or psychiatric
             illness that, in the investigators opinion places the patient at unacceptable risk and
             would prevent the subject from signing the informed consent form.

          2. Pregnant or breast feeding females.

          3. Known HIV infection. Patients with active hepatitis B infection (not including
             patients with prior hepatitis B vaccination; or positive serum Hepatitis B antibody).
             Known hepatitis C infection is allowed as long as there is no active disease and is
             cleared by GI consultation

          4. All patients with active central nervous system lymphoma.

          5. Significant neuropathy (Grades 3 - 4, or Grade 2 with pain) within 14 days prior to
             enrollment.

          6. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize
             carfilzomib).

          7. Contraindication to any of the required concomitant drugs or supportive treatments or
             intolerance to hydration due to preexisting pulmonary or cardiac impairment including
             pleural effusion requiring thoracentesis to ascites requiring paracentesis.

          8. Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30
             days of study enrollment).

          9. Patients with symptomatic bradycardia (heart rate &lt; 50 bpm, hypotension,
             light-headedness, syncope).

         10. Use of any standard/experimental anti-lymphoma drug therapy, including steroids,
             within 3 weeks of initiation of the study or use of any experimental non-drug therapy
             (e.g. donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the
             study drug treatment. Prior allogeneic SCT within 16 weeks or autologous SCT within 8
             weeks of initiation of therapy.

         11. Patients with New York Health Association (NYHA) Class III and IV heart failure,
             myocardial infarction in the preceding 6 months, and conduction abnormalities,
             including but not limited to atrial fibrillation, atrioventricular (AV) block block,
             QT prolongation, sick sinus syndrome, ventricular tachycardia, as these patients may
             be at greater risk for cardiac complication, per carfilzomib labeling.

         12. The patient has a prior or concurrent malignancy that in the opinion of the
             investigator, presents a greater risk to the patient's health and survival, than of
             the MCL, within the subsequent 6 months at the time of consent. Investigator
             discretion is allowed.

         13. Acute active infection requiring treatment (systemic antibiotics, antivirals, or
             antifungals) within 14 days prior to enrollment.

         14. Patients who have received any previous Carfilzomib treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hun J. Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <results_first_submitted>April 9, 2019</results_first_submitted>
  <results_first_submitted_qc>April 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2019</results_first_posted>
  <last_update_submitted>April 9, 2019</last_update_submitted>
  <last_update_submitted_qc>April 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>MCL</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>Carfilzomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02042950/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of 6 enrolled participants 2 failed screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Carfilzomib</title>
          <description>To evaluate the efficacy of single agent carfilzomib in patients with relapsed/refractory MCL as measured by response rate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carfilzomib</title>
          <description>To evaluate the efficacy of single agent carfilzomib in patients with relapsed/refractory MCL as measured by response rate.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate of Carfilzomib</title>
        <description>To evaluate the efficacy of single agent carfilzomib in patients with relapsed/refractory MCL as measured by response rate.</description>
        <time_frame>21 months</time_frame>
        <population>Unable to complete final analysis due to not meeting enrollment requirements.</population>
        <group_list>
          <group group_id="O1">
            <title>Carfilzomib</title>
            <description>To evaluate the efficacy of single agent carfilzomib in patients with relapsed/refractory MCL as measured by response rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate of Carfilzomib</title>
          <description>To evaluate the efficacy of single agent carfilzomib in patients with relapsed/refractory MCL as measured by response rate.</description>
          <population>Unable to complete final analysis due to not meeting enrollment requirements.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Toxicity of Carfilzomib</title>
        <description>To further evaluate the toxicity of Carfilzomib in patients</description>
        <time_frame>21 months</time_frame>
        <population>Unable to complete final analysis due to not meeting enrollment requirements.</population>
        <group_list>
          <group group_id="O1">
            <title>Carfilzomib</title>
            <description>To evaluate the efficacy of single agent carfilzomib in patients with relapsed/refractory MCL as measured by response rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity of Carfilzomib</title>
          <description>To further evaluate the toxicity of Carfilzomib in patients</description>
          <population>Unable to complete final analysis due to not meeting enrollment requirements.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Post Treatment</title>
        <description>To estimate the response duration, progression free survival, time to failure and overall survival.</description>
        <time_frame>21 months</time_frame>
        <population>Unable to complete final analysis due to not meeting enrollment requirements.</population>
        <group_list>
          <group group_id="O1">
            <title>Carfilzomib</title>
            <description>To evaluate the efficacy of single agent carfilzomib in patients with relapsed/refractory MCL as measured by response rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Post Treatment</title>
          <description>To estimate the response duration, progression free survival, time to failure and overall survival.</description>
          <population>Unable to complete final analysis due to not meeting enrollment requirements.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Carfilzomib</title>
          <description>To evaluate the efficacy of single agent carfilzomib in patients with relapsed/refractory MCL as measured by response rate.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry Eyes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema Limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alk Phos Increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>AST Increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bili Rubin Increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Creatinine Increase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophil Decrease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelet Count Decrease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>White Blood Cell Decrease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Elevated BUN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Elevated Lactic Acids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypocalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypomagnesium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hun Ju Lee/ Assistant Professor, Lymphoma/Myeloma</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 794-1829</phone>
      <email>hunlee@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

